Effect of metabolic control on the in vitro proliferation of peripheral blood mononuclear cells in type 1 and type 2 diabetic patients
Keywords:
Cell culture, Lymphocyte transformation, Type I diabetes mellitus, Type II diabetes mellitus, Hyperglycemia, InfectionAbstract
CONTEXT AND OBJECTIVE: Diabetes mellitus is a clinical syndrome that frequently leads to the development of chronic complications and high susceptibility to infections. It is probably due to defective immunological defense, which may be related to metabolic control of the disease. The aim of this study was to evaluate the effect of metabolic control on immune-cell behavior in type 1 and type 2 diabetic patients. For this, the in vi- tro proliferation of peripheral blood mononuclear cells (PBMC) was analyzed in patients with inad- equate and adequate metabolic control. DESIGN AND SETTING: Experimental/laboratory study at a university hospital. METHODS: Eleven type 1 and thirteen type 2 diabetic patients were studied, together with 21 healthy individuals divided in two groups (11/10), who were matched by sex and age with those diabetic patients. PBMC cultures stimulated with concanavalin-A (Con-A) were used to measure 3H-thymidine incorporation after 72 hours of cell culturing. For patients with inadequate metabolic control, culturing was per- formed on the first day of patient hospitalization and again after intensive treatment to achieve adequate control. RESULTS: The proliferation index for Con-A-stimu- lated cultures from type 1 diabetic patients was significantly greater than that for cultures from healthy individuals and type 2 diabetic patients, independent of metabolic control. A negative cor- relation between the proliferation cell index and body mass index and serum C-reactive protein levels was also observed. CONCLUSION: The increase in the prolifera- tion capacity of type 1 diabetic T lymphocytes was probably not caused by hyperglycemia and/or insulinopenia related to inadequate metabolic control.
Downloads
References
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-depen- dent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-86.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854-65.
Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med. 1999;341(25):1906-12.
Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26(2):510-3.
McMahon MM, Bistrian BR. Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect Dis Clin North Am. 1995;9(1):1-9.
Leibovici L, Yehezkelli Y, Porter A, Regev A, Krauze I, Hardell D. Influence of diabetes mellitus and glycaemic control on the characteristics and outcome of common infections. Diabet Med. 1996;13(5):457-63.
Golden SH, Peart-Vigilance C, Kao WH, Brancati FL. Perioperative glycemic control and the risk of infectious com- plication in a cohort of adults with diabetes. Diabetes Care. 1999;22(9):1408-14.
Savin JA. Bacterial infections in diabetes mellitus. Br J Dermatol. 1974;91(4):481-4.
Rodrigues DC, Taba MJ, Novaes AB, Souza SL, Grisi MF. Effect of non-surgical periodontal therapy on glycemic con- trol in patients with type 2 diabetes mellitus. J Periodontol. 2003;74(9):1361-7.
Bybee JD, Rogers DE. The phagocytic activity of polymorpho- nuclear leukocytes obtained from patients with diabetes mellitus. J Lab Clin Med. 1964;64:1-13.
Bagdade JD, Nielson KL, Bulger RJ. Reversible abnormalities in phagocytic function in poorly controlled diabetic patients. Am J Med Sci. 1972;263(6):451-6.
Stevens DL, Bryant AE, Huffman J, Thompson K, Allen RC. Analysis of circulating phagocyte activity measured by whole blood luminescence: correlations with clinical status. J Infect Dis. 1994;170(6):1463-72.
Saeed FA, Castle GE. Neutrophil chemiluminescence dur- ing phagocytosis is inhibited by abnormally elevated levels of acetoacetate: implications for diabetic susceptibility to infection. Clin Diagn Lab Immunol. 1998;5(5):740-3.
Gallacher SJ, Thomson G, Fraser WD, Fisher BM, Gemmell CG, MacCuish AC. Neutrophil bactericidal function in diabetes mellitus: evidence for association with blood glucose control. Diabet Med. 1995;12(10):916-20.
Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med. 1997;14(1):29-34.
Dolkart RE, Halpern B, Perlman J. Comparison of antibody responses in normal and alloxan diabetic mice. Diabetes. 1971;20(3):162-7.
Mahmoud AA, Rodman HM, Mandel MA, Warren KS. Induced and spontaneous diabetes mellitus and suppression of cell-mediated immunological responses. Granuloma formation, delayed dermal reactivity and allograft rejection. J Clin Invest. 1976;57(2):362-7.
Foss NT, de Oliveira EB, Silva CL. Correlation between TNF production, increase of plasma C-reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Int J Lepr Other Mycobact Dis. 1993;61(2):218-26.
Reinhold D, Ansorge S, Schleicher ED. Elevated glucose levels stimulate transforming growth factor-beta 1 (TGF-beta 1), suppress interleukin IL-2, IL-6 and IL-10 production and DNA synthesis in peripheral blood mononuclear cells. Horm Metab Res. 1996;28(6):267-70.
Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FESM Immunol Med Microbiol. 1999;26(3-4):259-65.
Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibil- ity of diabetic patients to specific infections. Diabete Metab. 1992;18(3):187-201.
Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflam- matory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53(8):2079-86.
Dandona P, Aljada A, Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia. 2002;45(6):924-30.
Herman A, Kappler JW, Marrack P, Pullen AM. Superantigens: mechanism of T-cell stimulation and role in immune responses. Annu Rev Immunol. 1991;9:745-72.
Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell. 1990;63(6):1249-56.
McCormack JE, Callahan JE, Kappler J, Marrack PC. Profound deletion of mature T-cells in vivo by chronic exposure to exog- enous superantigen. J Immunol. 1993;150(9):3785-92.
Kawabe Y, Ochi A. Programmed cell death and extrathymic reduction of Vbeta8+ CD4+ T cells in mice tolerant to Staphylo- coccus aureus enterotoxin B. Nature. 1991;349(6306):245-8.
Marrack P, Mitchell T, Bender J, et al. T-cell survival. Immunol Rev. 1998;165:279-85.
Gonzalo JA, Moreno de Alborán I, Alés-Martínez JE, Martínez C, Kroemer G. Expansion and clonal deletion of peripheral T cells induced by bacterial superantigen is independent of the interleukin-2 pathway. Eur J Immunol. 1992;22(4):1007-11.
